Kaplan-Meier survival plot of MET-1 tumor-bearing SCID/NOD mice in the large-tumor–burden therapeutic study.
At the time of the experiment, the mice had sIL-2Rα levels of 20 000 to 70 000 pg/mL. Mice in the control group did not receive any treatment. Mice in the HAT group received 100 μg HAT once per week for 4 weeks. Mice in the PRIT group or PRIT (no radionuclide, nr) group received 400 μg HAT-SA pretargeting for 24 hours, 100 μg sCA for 4 hours, and 1 μg DOTA-biotin labeled with 250 or 0 μCi (9.25 or 0 MBq) 213Bi. Mice in the PRIT + HAT group received the same pretargeting approach as those in the PRIT group, followed by 100 μg HAT once per week for 4 weeks. Mice in the PRIT (nonspecific, ns) group received 400 μg B3-SA pretargeting for 24 hours, 100 μg sCA for 4 hours, and 1 μg 213Bi–DOTA-biotin at a dose of 250 μCi (9.25 MBq). Mice in the RIT group received 50 μCi (1.85 MBq)213Bi-HAT.
